On December 3, 2025,  Vigonvita Life Science Co., Ltd. (2630.HK, hereinafter referred to as “Vigonvita”) entered into a licensing and collaboration agreement with Simcere Pharmaceutical Group (2096.HK, hereinafter referred to as “Simcere”). Under this agreement, Vigonvita will grant Simcere the exclusive rights to develop, manufacture, and commercialize VV116 for respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection in Greater China (including the Chinese mainland, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan region). Mr. Gaobo Zhou, Chief Investment Officer of Simcere, commented: “RSV affects people of all ages, and remains particularly harmful to infants, older adults, and individuals with weakened immune systems, for whom effective antiviral treatments are still limited. We are pleased to partner with Vigonvita to advance the development and commercialization of innovative antiviral therapies, with the hope of bringing more effective treatment options to patients as quickly as possible.” Dr. Guanghui Tian, Chairman and General Manager of Vigonvita, stated: “The dry suspension formulation of deuterated remididevir hydrobromide has received Breakthrough Therapy Designation and is expected to become the world’s first nucleoside-based antiviral approved for RSV. This exclusive licensing collaboration with Simcere will accelerate the development of indications for RSV and HMPV, with the goal…

On November 6, 2025, Vigonvita Life Sciences Co., Ltd., (hereinafter referred to as "Vigonvita") was officially listed on the Main Board of the Hong Kong Stock Exchange (hereinafter referred to as "HKEX") under the stock code 2630.HK. This marks the beginning of a new journey for Vigonvita in the field of medicine and health. At the listing ceremony, Dr. Tian Guanghui, Chairman and General Manager of Vigonvita, rang the opening bell to celebrate the company's successful listing on the Hong Kong stock market. The company's investors, partners, representatives from the intermediary institutions involved in this IPO, and staff members gathered together to personally witness and celebrate this milestone moment. Driven by innovation for high-quality development and guided by the mission to improve the health and quality of life for patients and their families, Vigonvita is committed to pioneering new drugs in the fields of neuropsychiatry, reproductive health, and viral infections. The company has established a fully integrated, end-to-end, and internally controlled functional system covering the entire industrial chain from innovative drug lead discovery, druggability optimization and evaluation, and preclinical research, to clinical studies, manufacturing, and clinical application. Within its highly clinically valuable and commercially competitive innovative drug pipeline, two new drugs have…

On September 4, 2025, the first offline prescription for simenafil hydrochloride tablets—a highly active, highly selective phosphodiesterase type 5 (PDE5) inhibitor featuring a novel chemical structure—was issued at the First Affiliated Hospital of Hunan University of Chinese Medicine. Prescribed for the treatment of erectile dysfunction (ED), this milestone marked the dawn of a new era for domestically developed innovative urological drugs in the field of ED therapy. ED is a common condition among adult males. The overall prevalence of ED in adult males is 26.1% [1], with a prevalence rate of 40.6% among men over 40 years old, which increases progressively with age [2]. However, the current rate of ED patients seeking medical treatment is only 13.4% [3]. PDE5 inhibitors, as the first-line treatment for ED [4], constitute the preferred initial therapy for the vast majority of patients. Nevertheless, the utilization rate of anti-ED medications in China remains low, at less than 5%. Beyond the influence of traditional beliefs and medical practices, concerns regarding the efficacy and safety of drug therapy may be significant contributing factors to this phenomenon. Simenafil hydrochloride exhibits potent inhibition of PDE5, with a clinically recommended starting dose significantly lower than that of marketed drugs targeting…

On 5th August 2025, Vigonvita Life Sciences Co., Ltd. (hereinafter referred to as ‘VIGONVITA’) held the official ceremony for the first batch shipment of Class 1 new drug, 昂伟达® Simenafil Hydrochloride Tablets, across the country. Company leaders and heads of relevant departments, along with leaders from the contract manufacturing organisation, witnessed this historic moment for VIGONVITA. 昂伟达® (Simenafil Hydrochloride Tablets) was approved for market by the National Medical Products Administration (NMPA) on 8th July for the treatment of erectile dysfunction (ED). As a high-potency, highly selective phosphodiesterase 5 (PDE5) inhibitor with a novel chemical structure, 昂伟达® demonstrates significant clinical efficacy, high safety, broad applicability, and diverse usage scenarios, positioning as a potential best-in-class drug and offering ED patients a new treatment option.   昂伟达® exhibits extreme inhibition effect of PDE5, with its clinically recommended starting dose significantly lower than that of currently marketed drugs with the same target. A Phase III clinical trial demonstrated that 昂伟达® exhibits significant clinical efficacy, with patients achieving normal erectile function scores after following the clinical protocol. 昂伟达® also demonstrates a notable safety advantage, with a lower incidence of adverse reactions compared to currently marketed drugs with the same target, and no reports of visual…

July 8, 2025 – 昂伟达® (Product Name: Simenafil Hydrochloride Tablets; R&D Code: TPN171), a Class 1 new drug collaboratively developed by Vigonvita Life Sciences Co., Ltd.,  Shanghai Institute of Materia Medica Chinese Academy of Sciences, Xinjiang Technical Institute of Physics and Chemistry  Chinese Academy of Sciences, and other institutions, has received marketing approval from the National Medical Products Administration (NMPA) for the treatment of Erectile Dysfunction (ED). 昂伟达® is a highly active and highly selective phosphodiesterase 5 (PDE5) inhibitor with a novel chemical structure. It demonstrates significant clinical efficacy, high safety, broad applicability across patient populations, and diverse usage scenarios. It possesses the potential to become a Best-in-Class drug, offering ED patients a superior treatment option. Non-clinical study results show that昂伟达® exhibits potent inhibition of PDE5 (IC₅₀ = 0.62 nM)[1] and significantly enhances penile erectile function in SD rats, Beagle dogs, and rabbits[2]. Phase III clinical trials demonstrated the significant clinical efficacy of 昂伟达®. Its recommended starting dose is lower than that of currently marketed drugs targeting with the same target. When taken on-demand at doses of 2.5 mg, 5 mg, and 10 mg, 昂伟达® achieved vaginal insertion success rates of 88.67%, 90.33%, and 92.02% respectively (40.58%, 42.43%, and 43.98% increase),…

In September 2024, the Provincial Department of Industry and Information Technology announced the sixth batch of enterprises that passed the review by the Ministry of Industry and Information Technology (MIIT) and were recognized as national-level specialized, sophisticated, distinctive, and innovative "Little Giant" enterprises. Among them, Vigonvita Life Sciences Co., Ltd. was awarded this honor. The "Specialized, Sophisticated, Distinctive and Innovative 'Little Giant'" designation is an honorary award specifically established by the state to encourage small and medium-sized enterprises (SMEs) to achieve development in four key areas: specialization in operations, refinement in output, distinctiveness in processes, and innovation in products. Its goal is to cultivate a group of "pacesetter enterprises" that focus on niche markets, possess strong innovation capabilities, hold significant market share, master core key technologies, and demonstrate excellent quality and efficiency, thereby enhancing the stability and competitiveness of industrial and supply chains.

  On August 27, 2024, Vigonvita Shanghai Co., Ltd., Shanghai Institute of Materia Medica Chinese Academy of Sciences, the Wuhan Institute of Virology Chinese Academy of Sciences, and Vigonvita Life Sciences Co., Ltd. ("Vigonvita") received the Drug Clinical Trial Approval Notice approved and issued by the National Medical Products Administration (NMPA), permitting the initiation of clinical trials for VV261 tablets for the treatment of Severe Fever with Thrombocytopenia Syndrome (SFTS) caused by infection with the novel Bunyavirus (SFTSV). SFTSV is an enveloped, negative-sense, single-stranded RNA virus that can infect humans and cause Severe Fever with Thrombocytopenia Syndrome. In severe cases, the disease can lead to death due to hemorrhage or multiple organ failure. SFTSV infection cases have been reported in China, Japan, South Korea, and Vietnam, with a fatality rate of around 7.8%. Currently, there are no approved therapeutic drugs available globally for the treatment of SFTSV infection. VV261 is a novel, orally administered nucleoside analog candidate drug with independent intellectual property rights. Preclinical research results have shown that VV261 exhibits significant antiviral efficacy in mouse models infected with SFTSV, and it demonstrates high oral bioavailability. Dr. Tian Guanghui, General Manager of Vigonvita, stated: "VV261 is the first domestically developed small molecule…

From January 29 to 30, 2024, a “randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the safety and efficacy of Deuremidevir Hydrobromide dry suspension in hospitalized infants and children with Respiratory Syncytial Virus infection” was successfully initiated at Shulan (Hangzhou) Hospital, Linfen Central Hospital, and Mianyang Central Hospital. This signifies that Deuremidevir Hydrobromide (V116) dry suspension for the treatment of Respiratory Syncytial Virus (RSV) infection in infants and children has officially advanced to the Phase II clinical trial stage. The study is a randomized, double-blind, placebo-controlled multicenter trial, aimed at evaluating the safety, efficacy, and pharmacokinetic characteristics of different doses of VV116 dry suspension in treating RSV infection in infants and children. Li Lanjuan, an academician of the Chinese Academy of Engineering and a renowned infectious disease scientist in China, serves as the leading principal investigator (Leading PI) of this research. The plan is to enroll 60 subjects, with participation from 20 research centers nationwide. RSV, a single-stranded, negative-sense RNA virus, is capable of causing respiratory infections in individuals across all age groups. It is particularly impactful on infants, the elderly, and adults with immune deficiencies or underlying diseases, potentially leading to severe infections and respiratory sequelae. RSV is a major…

From December 15 to 17, 2023, the ‘24th World Meeting on Sexual Medicine’ hosted by the International Society for Sexual Medicine (ISSM) was held in Dubai, UAE. This conference brought together more than 500 sexual medicine experts and scholars from over 100 countries and regions around the world to discuss the latest research achievements and challenges in the field of sexual medicine. At this Sexual Medicine Meeting, Vigonvita showcased ONVITA® (TPN171), an innovative drug for the treatment of Erectile Dysfunction (ED). Renowned sexual medicine experts, scholars, and pharmaceutical representatives from around the world discussed the mechanism of action and clinical research results of ONVITA®, as well as the possibility of future cooperation with representatives from Vigonvita. TPN171 is a novel highly selective phosphodiesterase type 5 (PDE5) inhibitor, which can be used for the treatment of ED. TPN171 has significant clinical efficacy, and the effective dose is lower than that of drugs with the same target, with a clinically recommended dose of 5 mg. In a randomized, double-blind, placebo-controlled, multi-center phase III clinical trial, 765 ED patients took 2.5 mg, 5 mg, 10 mg of TPN171 or placebo for 12 weeks. The results showed that all dosage groups of TPN171 significantly…

November 23, 2023, Beijing time The results of a phase Ⅲ clinical study of the domestic COVID-19 oral drug Mindvy® (Deuremidevir hydrobromide tablets, product code: VV116/JT001) co-developed by Vigonvita, were published on the authoritative periodical in the field of infectious diseases , The Lancet Infectious Diseases (IF: 56.3); previously the results of the "head-to-head" phase Ⅲ clinical study (NCT05341609) were published in the top international medical journal, New England Journal of Medicine (IF:158.5); and now the results of the Phase III clinical study (NCT05582629) are published in an international authoritative medical journal again.This marks the international academic community's recognition for the efficacy and safety of the domestic original innovative COVID-19 oral drug Mindvy®. [caption id="attachment_136" align="aligncenter" width="958"] Source: Official website of The Lancet Infectious Diseases[/caption] This clinical study was led by Academician Li Lanjuan, Director of the State Key Laboratory of Diagnosis and Treatment of Infectious Diseases at Zhejiang University, and was conducted in 31 hospitals across China. Statistically and clinically significant results were obtained in the interim analysis of the study. Compared with placebo, treatment of adult patients (≥18 years old) with mild to moderate COVID-19 infection with Mindvy® significantly shortened the disappearance time of 11 clinical symptoms, including…

On the morning of November 12, 2023 Eastern Time, USA, the results of the Phase IIa clinical trial (ClinicalTrials. gov ID: NCT04483115) of TPN171H tablets for the treatment of pulmonary arterial hypertension were announced at the 2023 (AHA Scientific Sessions) Featured Science. This is a clinical study jointly led by Professor Yong Huo of Peking University First Hospital and Professor Zhicheng Jing of Peking Union Medical College Hospital, and jointly sponsored by Vigonvita Life Sciences Co., Ltd. and SIMM Chinese Academy of Sciences, to explore the impact of a single oral dose of TPN171H tablet on acute hemodynamics in patients with pulmonary arterial hypertension. This study is a multicenter, randomized, double-blind, placebo, and positive control phase IIa clinical trial. A total of 60 Chinese patients with pulmonary hypertension were included in the trial, divided into 6 groups with 10 people in each group. They were respectively assigned to the placebo group, the experimental drug 2.5 mg, 5 mg, 10 mg groups, and the tadalafil 20 mg and 40 mg groups. Collect baseline hemodynamic parameters from subjects after Swan Ganz floating catheter placement to evaluate acute hemodynamic changes within 24 hours after administration. The experimental results showed that compared to the…

On November 2, 2023, an expert discussion meeting on the Phase II/III clinical trial protocol for the treatment of respiratory syncytial virus (RSV) infection in infants and young children with deuremidevir hydrobromide (VV116) was successfully held at Shulan (Hangzhou) Hospital, adopting a combination of online and offline.